This content is from: Portfolio Proxy Advisors Back Allergan Over Appaloosa in Latest Scuffle Appaloosa wants to replace Allergan’s chairman and install an independent pharmaceutical executive in that role. ISS and Glass Lewis recommend that shareholders vote against it. By Alicia McElhaney April 15, 2019
This content is from: Premium Mergers Boost David Tepper’s Appaloosa Tepper’s fund and other hedge funds are benefiting from this week’s deals to acquire Caesars and Allergan. By Stephen Taub June 25, 2019
This content is from: Premium Appaloosa Alum Matthew Knauer’s Nokota Mounts a Comeback After a tough year including a co-founder’s departure and stark losses, Nokota matched its best year ever in 2019. By Stephen Taub January 29, 2020
This content is from: Portfolio David Tepper’s Appaloosa Sees Steep Decline in Assets Here is what led to the hedge fund firm’s drop in assets, according to a person with knowledge of the matter. By Steve Taub March 29, 2019
This content is from: Premium David Tepper’s Appaloosa Sharply Boosts Bet on U.S. Stocks The eclectic investment firm increased the size of its stock portfolio for the first time in four quarters. By Stephen Taub May 17, 2019
This content is from: Premium Tepper’s Appaloosa Slashes Stock Portfolio The hedge fund firm is down slightly this year through October, according to an investor. By Steve Taub November 15, 2018
Sponsored Who’s on Your Equities Watch List? And, more importantly, how might they fit and function in your overall portfolio? This PM and his team relentlessly search for the answers. Sponsored by Mackenzie Investments April 01, 2020
